Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults - Comparison between Sweden, The Netherlands and Germany

European Journal of Endocrinology

Volumn 154, Issue 6, 2006, Pages 843-850

  Saller, Bernhard ^a,e   Mattsson, Anders F ^a   Kann, Peter H ^b   Koppeschaar, Hans P ^c   Svensson, Johan ^d   Pompen, Marjolein ^a   Koltowska Häggström, Maria ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e EndoScience   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GROWTH HORMONE; HYDROCORTISONE; SOMATOMEDIN C; TESTOSTERONE; THYROID HORMONE; VASOPRESSIN;

ABSENTEEISM; ADULT; ARTICLE; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; CRANIOPHARYNGIOMA; EUROPE; FEMALE; FOLLOW UP; GERMANY; GROWTH HORMONE DEFICIENCY; HEALTH CARE UTILIZATION; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSECTOMY; HYPOPHYSIS ADENOMA; HYPOTHALAMUS TUMOR; LEISURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; NETHERLANDS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RACE DIFFERENCE; SWEDEN; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; FEMALE; GERMANY; HEALTH RESOURCES; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NETHERLANDS; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SWEDEN;

EID: 33745698801     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02149     Document Type: Article

References (39)

1. Arwert LI, Deijen JB, Muller M & Drent ML. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Hormones and Behaviour 2005 47 343-349.
2. Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L & Isaksson OG. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. Journal of Clinical Endocrinology and Metabolism 1993 76 309-317.
3. Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E & Karlsson FA. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. Journal of Clinical Endocrinology and Metabolism 1995 80 3585-3590.
4. Colao A, di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M & Lombardi G. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. Journal of Clinical Endocrinology and Metabolism 2002 87 1088-1093.
5. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW & Hurley D. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism 1998 83 107-116.
6. Cuneo RC, Salomon F, Watts GF, Hesp R & Sonksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993 42 1519-1523.
7. Cuneo RC, Salomon F, Wiles CM, Hesp R & Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. Journal of Applied Physiology 1991 70 695-700.
8. de Boer H, Blok GJ, Voerman B, Derriks P & van der Veen E. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. International Journal of Obesity and Related Metabolic Disorders 1996 20 580-587.
9. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B & Johannsson G. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. Journal of Clinical Endocrinology and Metabolism 2001 86 4657-4665.
10. Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GF, Biller BM, Clark RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phillips LS, Ridgway EC, Robbins RJ, Schlechte J, Sharma M, Thorner MO & Vance ML. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 2048-2056.
11. Johannsson G, Rosen T, Bosaeus I, Sjostrom L & Bengtsson BA. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. Journal of Clinical Endocrinology and Metabolism 1996 81 2865-2873.
12. Oertel H, Schneider HJ, Stalla GK, Holsboer F & Zihl J. The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism. Psychoneuroendocrinology 2004 29 839-850.
13. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalova J, Moshang T, Blum WF, Chipman JJ, Quigley CA & Attanasio AF. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. Journal of Clinical Endocrinology and Metabolism 2003 88 4124-4129.
14. Hernberg-Stahl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton F, Westberg B & Monson JP. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 5277-5281.
15. Svensson J, Mattsson A, Rosen T, Wiren L, Johannsson G, Bengtsson BA & Koltowska Haggstrom M. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Hormone and IGF Research 2004 14 207-215.
16. McKenna SP, Doward LC, Alonso J, Kohlmann T & Niero M. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999 8 373-383.
17. Johannsson G, Mattsson AF, Koltowska-Haggstrom M & Monson JP. Long-Term Growth Hormone Replacement (GHR) in Hypopituitary Adults with Growth Hormone Deficiency (GHD) Leads towards Normalization in Quality of Life (QoL), Measured by Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Instrument In: ENDO 2005 San Diego: The Endocrine Society, 2005.
18. Wiren L, Whalley D, McKenna S & Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by rasch analysis. Clinical Endocrinology (Oxf) 2000 52 143-152.
19. Blum WF, Shavrikova EP, Edwards DJ, Rosilio M, Hartman ML, Marin F, Valle D, van der Lely AJ, Attanasio AF, Strasburger CJ, Henrich G & Herschbach P. Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, questions on life satisfaction hypopituitarism module. Journal of Clinical Endocrinology and Metabolism 2003 88 4158-4167.
20. Koltowska-Haggstrom M, Hennessy S, Mattsson AF, Monson JP & Kind P. Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency. Hormone Research 2005 64 46-54.
21. Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, Lamberts SW, Erfurth EM, Webb SM, Ross RJ, Chihara K, Henrich G, Herschbach P & Attanasio AF. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). Journal of Clinical Endocrinology and Metabolism 2004 89 1684-1693.
22. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P & Wuster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. Journal of Clinical Endocrinology and Metabolism 1999 84 3929-3935.
23. Drake WM, Howell SJ, Monson JP & Shalet SM. Optimizing gh therapy in adults and children. Endocrine Reviews 2001 22 425-450.
24. Mukherjee A, Monson JP, Jonsson PJ, Trainer PJ & Shalet SM. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. Journal of Clinical Endocrinology and Metabolism 2003 88 5865-5870.
25. Burman P, Johansson AG, Siegbahn A, Vessby B & Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. Journal of Clinical Endocrinology and Metabolism 1997 82 550-555.
26. Cook DM, Ludlam WH & Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 1999 84 3956-3960.
27. Federal health monitoring system. Federal Statistical Office and Robert-Koch-Institut. http//www.gbe-bund.de.
28. Socialstyrelsen. The national board of health and welfare. http// statline.cbs.nl.
29. Statistics Netherlands. http//www.sos.se.
30. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism, West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431.
31. Wiren L, Bengtsson BA & Johannsson G. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clinical Endocrinology (Oxf) 1998 48 613-620.
32. Jorgensen JO, Vahl N, Hansen TB, Thuesen L, Hagen C & Christiansen JS. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clinical Endocrinology (Oxf) 1996 45 681-688.
33. Cuneo RC, Salomon F, Wiles CM & Sonksen PH. Skeletal muscle performance in adults with growth hormone deficiency. Hormone Research 1990 33(Suppl 4) 55-60.
34. Christ ER, Cummings MH, Westwood NB, Sawyer BM, Pearson TC, Sonksen PH & Russell-Jones DL. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1997 82 2985-2990.
35. McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatrica Scandinavia Supplement 1989 356 70-74.
36. Sartorio A, Molinari E, Riva G, Conti A, Morabito F & Faglia G. Growth hormone treatment in adults with childhood onset growth hormone deficiency: effects on psychological capabilities. Hormone Research 1995 44 6-11.
37. Lai ZN, Emtner M, Roos P & Nyberg F. Characterization of putative growth hormone receptors in human choroid plexus. Brain Research 1991 546 222-226.
38. Burman P, Hetta J, Wide L, Mansson JE, Ekman R & Karlsson FA. Growth hormone treatment affects brain neurotransmitters and thyroxine. Clinical Endocrinology (Oxf) 1996 44 319-324.
39. Johansson JO, Larson G, Andersson M, Elmgren A, Hynsjo L, Lindahl A, Lundberg PA, Isaksson OG, Lindstedt S & Bengtsson BA. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology 1995 61 57-66.